3. World Health Organization. Treatment of tuberculosis: guidelines 2010. Geneva: World Health Organization; 2010.
4. Choi R, Jeong BH, Koh WJ, Lee SY. Recommendations for optimizing tuberculosis treatment: therapeutic drug monitoring, pharmacogenetics, and nutritional status considerations. Ann Lab Med 2017;37:97-107.
5. Arbex MA, Varella Mde C, Siqueira HR, Mello FA. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs. J Bras Pneumol 2010;36:626-40.
6. Sarkar S, Ganguly A, Sunwoo HH. Current overview of antituberculosis drugs: metabolism and toxicities. Mycobact Dis 2016;6:2.
7. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979;4:401-22.
9. Um SW, Lee SW, Kwon SY, Yoon HI, Park KU, Song J, et al. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis 2007;11:972-8.
10. Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014;74:839-54.
12. Seifart HI, Parkin DP, Botha FJ, Donald PR, Van Der Walt BJ. Population screening for isoniazid acetylator phenotype. Pharmacoepidemiol Drug Saf 2001;10:127-34.
14. Matsumoto T, Ohno M, Azuma J. Future of pharmacogenetics-based therapy for tuberculosis. Pharmacogenomics 2014;15:601-7.
16. Kubota R, Ohno M, Hasunuma T, Iijima H, Azuma J. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2. Eur J Clin Pharmacol 2007;63:927-33.
17. Wattanapokayakit S, Mushiroda T, Yanai H, Wichukchinda N, Chuchottawon C, Nedsuwan S, et al.
NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients. Int J Tuberc Lung Dis 2016;20:1364-9.
18. Wichukchinda N, Pakdee J, Kunhapan P, Imunchot W, Toyo-Oka L, Tokunaga K, et al. Haplotype-specific PCR for
NAT2 diplotyping. Hum Genome Var 2020;7:13.
21. Leiro-Fernandez V, Valverde D, Vazquez-Gallardo R, BotanaRial M, Constenla L, Agundez JA, et al. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuberc Lung Dis 2011;15:1403-8.
22. Singh N, Dubey S, Chinnaraj S, Golani A, Maitra A. Study of
NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients. Mol Diagn Ther 2009;13:49-58.
24. Teixeira RL, Morato RG, Cabello PH, Muniz LM, Moreira Ada S, Kritski AL, et al. Genetic polymorphisms of
NAT2,
CYP2E1 and
GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz 2011;106:716-24.
25. Lv X, Tang S, Xia Y, Zhang Y, Wu S, Yang Z, et al.
NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population. Ann Hepatol 2012;11:700-7.
26. Ng CS, Hasnat A, Al Maruf A, Ahmed MU, Pirmohamed M, Day CP, et al. N-acetyltransferase 2 (
NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. Eur J Clin Pharmacol 2014;70:1079-86.